CoChat

Pharmacotherapy for social anxiety disorder

Stein, Dan J, Ipser, Jonathan C, van Balkom, Anton J · 2004 · Cochrane Database of Systematic Reviews
Cited by 102

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Social phobia (SP), or social anxiety disorder, is a prevalent and disabling disorder. There is growing evidence that SP is mediated by specific neurobiological factors, and increased interest in the use of medication in its treatment. OBJECTIVES: To assess the effects of pharmacotherapy for Social Phobia, and to determine whether particular classes of medication are more effective and/or acceptable than others in its treatment. SEARCH STRATEGY: Studies of the pharmacotherapy of SP were identified using literature searches of the Cochrane Depression, Anxiety & Neurosis Group (CCDAN) specialised register, the Cochrane Central Register of Controlled Trials (The Cochrane Library issue 1, 2004), MEDLINE (1966 to 2003) and PsycLit (1966 to 2003). In addition, published and unpublished RCTs were requested from SP researchers and pharmaceutical companies and additional studies of any language were sought in reference lists of retrieved articles. SELECTION CRITERIA: All RCTs of the pharmacotherapy of SP were considered for the review. DATA COLLECTION AND ANALYSIS: The quality of selected RCTs was independently assessed by 2 raters on the CCDAN Quality Rating Scale, with the same raters collating data on treatment response and SP symptom ratings. Investigators were contacted to obtain missing data. Summary statistics were stratified by medication class (SSRIs - selective serotonin reuptake inhibitors; MAOIs - Monoamine oxidase inhibitors; RIMAs - reversible inhibitors of monoamine oxidase A), from which dichotomous and continuous measures were calculated, heterogeneity was assessed, and subgroup/sensitivity analyses undertaken. MAIN RESULTS: 36 RCTs of a range of medications were included in the analysis (4268 participants), of which 26 were short-term (14 weeks or less). A funnel plot provided evidence of publication bias. Summary statistics for responder status (assessed using the Clinical Global Impressions scale change item (CGI-C)) from 25 short-term comparisons demonstrated superiority of various medication agents over placebo (relative risk of non-response (RR) = 0.63; 95% CI = 0.55, 0.72; random effects model). Response to treatment by serotonin reuptake inhibitors (N = 11; RR = 0.67; 95% CI = 0.59, 0.76), MAOIs (N = 3; RR = 0.43; 95% CI = 0.24, 0.76) and RIMAs (N = 6; RR = 0.74; 95% CI = 0.59, 0.91) supported the value of these agents. However, the SSRIs were significantly more effective than the RIMAs (Deeks' stratified test of heterogeneity (Deeks 2001): Qb = 29.82; p < 0.00001). Summary statistics for SP symptoms from 16 comparisons using the Liebowitz Social Anxiety Scale (LSAS) showed a statistically significant difference between medication and placebo (weighed mean difference = -15.56, 95%CI = -17.95, -13.16), with this effect once again most evident for the SSRIs. Medication was also significantly superior to placebo in reducing SP symptom clusters, comorbid depressive symptoms, and associated disability. The value of long-term medication treatment in treatment responders was supported by 3 comparisons from maintenance studies (relative risk of non-response = 0.58; 95% CI = 0.39, 0.85) and 5 comparisons from relapse prevention studies (relative risk of relapse = 0.33; 95% CI = 0.22, 0.49). REVIEWERS' CONCLUSIONS: This review provides evidence that medication can be effective in treating SP over the short term, with the strongest evidence of treatment efficacy observed amongst the SSRIs. Furthermore, the data support continued pharmacotherapy in medication responders over the longer-term. Nevertheless, the possibility of publication has to be acknowledged. Additional issues for future research include the use of medication in children and adolescents with SP, and in SP with comorbid psychiatric disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd001206.pub2

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 95

  1. Allgulander, 1999, Paroxetine in social social anxiety disorder: a randomised placebo-controlled study, Acta Psychiatrica Scandinavica, 100, 193, 10.1111/j.1600-0447.1999.tb10845.x · DOI · Paper page
  2. Baldwin, 1999, Paroxetine in social phobia /social anxiety disorder. Randomised, double-blind, placebo-controlled study, British Journal of Psychiatry, 175, 120, 10.1192/bjp.175.2.120 · DOI · Paper page
  3. Barnett, 2002, Efficacy of olanzapine in social anxiety disorder: a pilot study, Journal of Psychopharmacology, 16, 365, 10.1177/026988110201600412 · DOI · Paper page
  4. Blomhoff, 2001, Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia, British Journal of Psychiatry, 179, 23, 10.1192/bjp.179.1.23 · DOI · Paper page
  5. Clark, 1991, The assessment and treatment of performance anxiety in musicians, American Journal of Psychiatry, 148, 598, 10.1176/ajp.148.5.598 · DOI · Paper page
  6. Connor, 1998, Discontinuation of clonazepam in the treatment of social phobia, Journal of Clinical Psychopharmacology, 18, 373, 10.1097/00004714-199810000-00004 · DOI · Paper page
  7. Davidson, 1993, Treatment of social phobia with clonazepan and placebo, Journal of Clinical Psychopharmacology, 13, 423, 10.1097/00004714-199312000-00008 · DOI · Paper page
  8. Fahlen, 1995, Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study, Acta Psychiatrica Scandinavica, 92, 351, 10.1111/j.1600-0447.1995.tb09596.x · DOI · Paper page
  9. James, 1983, Effect on pindolol on stress-related disturbances of musical performance: preliminary communication, Journal of the Royal Society of Medicine, 76, 194, 10.1177/014107688307600308 · DOI · Paper page
  10. Katschnig, 1997, Moclobemide in social phobia. A double-blind, placebo-controlled clinical study, European Archives of Psychiatry and Clinical Neuroscience, 247, 71
  11. Katzelnick, 1995, Sertraline for social phobia: A double-blind, placebo-controlled crossover study, American Journal of Psychiatry, 152, 1368, 10.1176/ajp.152.9.1368 · DOI · Paper page
  12. Kobak, 2002, Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study, Journal of Clinical Psychopharmacology, 22, 257, 10.1097/00004714-200206000-00005 · DOI · Paper page
  13. Liebowitz, 2002, A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder, Journal of Clinical Psychiatry, 63, 66, 10.4088/JCP.v63n0113 · DOI · Paper page
  14. Liebowitz, 2003, Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study, Journal of Clinical Psychiatry, 64, 785, 10.4088/JCP.v64n0708 · DOI · Paper page
  15. Lott, 1997, Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study, Journal of Clinical Psychopharmacology, 17, 255, 10.1097/00004714-199708000-00003 · DOI · Paper page
  16. Noyes, 1997, Moclobemide in social phobia: A controlled dose response trial, Journal of Clinical Psychopharmacology, 17, 247, 10.1097/00004714-199708000-00002 · DOI · Paper page
  17. Oosterbaan, 2001, Cognitive therapy versus moclobemide in social phobia: A controlled study, Clinical Pscyhology and Psychotherapy, 8, 263, 10.1002/cpp.291 · DOI · Paper page
  18. Pande, 1999, Treatment of social phobia with gabapentin: a placebo-controlled study, Journal of Clinical Psychopharmacology, 19, 341, 10.1097/00004714-199908000-00010 · DOI · Paper page
  19. Randall, 2001, Paroxetine for social anxiety and alcohol use in dual-diagnosed patients, Depression & Anxiety, 14, 255, 10.1002/da.1077 · DOI · Paper page
  20. Schneier, 1998, Placebo-controlled trial of moclobemide in social phobia., British Journal of Psychiatry, 172, 70, 10.1192/bjp.172.1.70 · DOI · Paper page
  21. Stein, 1996, Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation, Journal of Clinical Psychopharmacology, 16, 218, 10.1097/00004714-199606000-00005 · DOI · Paper page
  22. Stein, 1998, Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial, JAMA, 280, 708, 10.1001/jama.280.8.708 · DOI · Paper page
  23. Stein, 1999, Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study, American Journal of Psychiatry, 156, 756, 10.1176/ajp.156.5.756 · DOI · Paper page
  24. Stein, 2002, Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder, International Clinical Psychopharmacology, 17, 161, 10.1097/00004850-200207000-00002 · DOI · Paper page
  25. Stein, 2002, Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study, Archives of General Psychiatry, 59, 1111, 10.1001/archpsyc.59.12.1111 · DOI · Paper page
  26. Stein, 2003, Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial., International Journal of Neuropsychopharmacology, 6, 317, 10.1017/S146114570300364X · DOI · Paper page
  27. Turner, 1994, Social phobia: A comparison of behaviour therapy and atenolol, Journal of Consulting and Clinical Psychology, 62, 350, 10.1037/0022-006X.62.2.350 · DOI · Paper page
  28. Ameringen, 2001, Sertraline treatment of generalised social phobia: a 20-week, double-blind, placebo-controlled study, American Journal of Psychiatry, 158, 275, 10.1176/appi.ajp.158.2.275 · DOI · Paper page
  29. Vliet, 1992, Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor, European Neuropsychopharmacology, 2, 21, 10.1016/0924-977X(92)90032-4 · DOI
  30. Vliet, 1994, Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine, Psychopharmacology, 115, 128, 10.1007/BF02244762 · DOI · Paper page
  31. Vliet, 1997, Clinical effects of busiprone in social phobia: a double-blind placebo-controlled study, Journal of Clinical Psychiatry, 58, 164, 10.4088/JCP.v58n0405 · DOI · Paper page
  32. Versiani, 1992, Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine., British Journal of Psychiatry, 161, 353, 10.1192/bjp.161.3.353 · DOI · Paper page
  33. Versiani, 1997, Double-blind placebo controlled trial with bromazepam in social phobia, Jornal Brasileiro de Psiquiatria, 46, 167
  34. Allsopp, 1984, Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice, Current Medical Research and Opinion, 9, 64, 10.1185/03007998409109561 · DOI · Paper page
  35. Atmaca, 2002, Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings, Human Psychopharmacology, 2002, 401, 10.1002/hup.436 · DOI · Paper page
  36. Falloon, 1981, The treatment of social phobia: Real-life rehearsal with nonprofessional therapists, Journal of Nervous and Mental Disease, 169, 180, 10.1097/00005053-198103000-00005 · DOI · Paper page
  37. Gates, 1985, Effect of beta-blockage on singing performance., Annals of Otology, Rhinology and Laryngology, 94, 570, 10.1177/000348948509400609 · DOI · Paper page
  38. Hartley, 1983, The effect of beta adrenergic blockade on speaker's performance and memory, British Journal of Psychiatry, 142, 512, 10.1192/bjp.142.5.512 · DOI · Paper page
  39. James, 1977, Effect of oxprenolol on stage-fright in musicians, Lancet, 2, 952, 10.1016/S0140-6736(77)90890-X · DOI
  40. James, 1984, Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo, American Heart Journal, 108, 1150, 10.1016/0002-8703(84)90599-4 · DOI
  41. Krishman, 1976, Oxprenolol in the treatment of examination stress, Current Medical Research and Opinion, 4, 241, 10.1185/03007997609109311 · DOI
  42. Liappas, 2003, Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration, Journal of Affective Disorders, 76, 279, 10.1016/S0165-0327(02)00094-0 · DOI
  43. Liden, 1974, Beta-blocking agents in the treatment of catecholamine-induced symptoms in musicians, Lancet, 2, 529, 10.1016/S0140-6736(74)92060-1 · DOI
  44. Liebowitz, 1988, Pharmacotherpy of social phobia: An interim report of placebo-controlled comparison of phenelzine and atenolol, Journal of Clinical Psychiatry, 49, 252
  45. Liebowitz, 1999, Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome, Depression and Anxiety, 10, 89, 10.1002/(SICI)1520-6394(1999)10:3<89::AID-DA1>3.0.CO;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
  46. Mountjoy, 1977, A clinical trial of phenelzine in anxiety depressive and phobic neuroses, British Journal of Psychiatry, 131, 486, 10.1192/bjp.131.5.486 · DOI · Paper page
  47. Neftel, 1982, Stage fright in musicians: A model illustrating the effect of beta blockers, Psychosomatic Medicine, 44, 461, 10.1097/00006842-198211000-00008 · DOI · Paper page
  48. Oosterbaan D van Balkom A Spinhoven van Dyk R Cognitive behavior therapy versus moclobemide in social phobia WPA Thematic Conference, Jerusalem, Nov 1997
  49. Pecknold, 1982, Does tryptophan potentiate clomipramine in the treatment of agoraphobic and agoraphobicand social pobic patients, British Journal of Psychiatry, 140, 484, 10.1192/bjp.140.5.484 · DOI
  50. 2001, Fluvoxamine for the treatment of anxiety disorders in children and adolescents, New England Journal of Medicine, 34, 1279
  51. Seedat, 2001, Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study, American Journal of Psychiatry, 158, 1725, 10.1176/appi.ajp.158.10.1725 · DOI · Paper page
  52. Siitonen, 1976, Effect of beta-blockade during bowling competition, Annals of Clinical Research, 8, 393
  53. Silverstone, 1973, Controlled evaluation of intravenous drugs in the specific desensitization of phobias, Canadian Psychiatric Association Journal, 18, 47, 10.1177/070674377301800109 · DOI
  54. Solyom, 1973, Behaviour therapy versus drug therapy in the treatment of phobic neurosis, Canadian Psychiatric Association Journal, 18, 25, 10.1177/070674377301800106 · DOI · Paper page
  55. Solyom, 1981, Phenelzine and exposure in the treatment of phobias, Biological Psychiatry, 16, 239
  56. Tyrer, 1973, A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety, Psychopharmacologica, 32, 237, 10.1007/BF00422146 · DOI
  57. Allgulander, 2004, Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine, Human Psychopharmacology, 19, 387, 10.1002/hup.602 · DOI · Paper page
  58. Stein, 2005, Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial., Psychopharmacology, 177, 280, 10.1007/s00213-004-1957-9 · DOI
  59. Aarre, 2003, Phenelzine efficacy in refractory social anxiety disorder: a case series., Nordic Journal of Psychiatry, 57, 313, 10.1080/08039480310002110 · DOI · Paper page
  60. 1980, Diagnostic and Statistical Manual of Mental Disorders
  61. Bailar, 1999, The promise and problems of meta-analysis, New England Journal of Medicine, 337, 559, 10.1056/NEJM199708213370810 · DOI · Paper page
  62. Ballenger, 1998, Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety, Journal of Clinical Psychiatry, 59 Suppl 17, 54
  63. Bandelow, 2002, WFSBP Task Force on Treatment Guidelines for Anxiety O-CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders, World Journal of Biological Psychiatry, 3, 171, 10.3109/15622970209150621 · DOI · Paper page
  64. Berlin, 1999, Measuring the quality of trials: The quality of quality scales, JAMA, 282, 1083, 10.1001/jama.282.11.1083 · DOI
  65. Blanco, 2003, Pharmalogical treatment of social anxiety disorder: A meta-analysis, Depression and Anxiety, 18, 29, 10.1002/da.10096 · DOI · Paper page
  66. Chambless, 1979, Flooding with brevital in the treatment of agoraphobia - countereffective?, Behav Res Ther, 17, 243, 10.1016/0005-7967(79)90039-1 · DOI
  67. Davidson, 1991, Long-term treatment of social phobia with clonazepam, Journal of Clinical Psychiatry, 52 Suppl 1, 16
  68. Davidson, 1998, Pharmacotherapy of social anxiety disorder., Journal of Clinical Psychiatry, 59 Suppl 17, 47
  69. Deeks, 2003, Cochrane Reviewers’ Handbook 4.2.1 [updated December 2003]
  70. Dickersin, 1992, Factors influencing the publication of research results: Follow-up of applications submitted to two substantial review boards, JAMA, 267, 374, 10.1001/jama.1992.03480030052036 · DOI · Paper page
  71. Fahlen, 1995, Personality traits in social phobia, II: Changes during drug treatment, Journal of Clinical Psychiatry, 56, 569
  72. Gorman, 1987, Drug treatment of social phobia, Journal of Affective Disorders, 13, 183, 10.1016/0165-0327(87)90022-X · DOI
  73. Gould, 1997, Cognitive-behavioral and pharmacological treatments of social phobia, Clinical Psychology - Science & Practice, 4, 291, 10.1111/j.1468-2850.1997.tb00123.x · DOI · Paper page
  74. Guy, 1976, ECDEU assessment manual for psychopharmacology
  75. Hamilton, 1959, The assessment of anxiety states by rating, British Journal of Medical Psychology, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  76. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  77. Kelsey, 1995, Venalafaxine in social phobia., Psychopharmacology Bulletin, 31, 767
  78. Kessler, 1994, Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United Sates: results from the National Comorbidity Survey, Archives of General Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
  79. Kuzma, 2004, Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders, Curr Psychiatry Rep., 6, 268, 10.1007/s11920-004-0076-y · DOI
  80. Liebowitz, 1985, Social phobia. Review of a neglected anxiety disorder., Archives of General Psychiatry, 42, 729, 10.1001/archpsyc.1985.01790300097013 · DOI · Paper page
  81. Liebowitz, 2002, A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder, Journal of Clinical Psychiatry, 63, 66, 10.4088/JCP.v63n0113 · DOI · Paper page
  82. Lincoln, 2004, How much do sample characteristics affect the effect size? An investigation of studies testing the treatment effects for social phobia., Journal of Anxiety Disorders, 18, 515, 10.1016/S0887-6185(03)00040-9 · DOI
  83. Marks, 1966, Different ages of onset in varieties of phobias, American Journal of Psychiatry, 123, 218, 10.1176/ajp.123.2.218 · DOI · Paper page
  84. Matsunaga, 2001, Taijin kyofusho: A form of social anxiety disorder that repsonds to serotonin reuptake inhibitors?, International Journal of Neuropsychopharmacology, 4, 231, 10.1017/S1461145701002474 · DOI · Paper page
  85. Moher, 1999, Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement, Lancet, 354, 1896, 10.1016/S0140-6736(99)04149-5 · DOI · Paper page
  86. Mulrow, 1997, Cochrane Collaboration Handbook
  87. Schneier, 2003, Citalopram treatment of social anxiety disorder with comorbid major depression, Depress and Anxiety, 17, 191, 10.1002/da.10112 · DOI · Paper page
  88. Song, 2003, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses, British Medical Journal, 326, 472, 10.1136/bmj.326.7387.472 · DOI · Paper page
  89. Stein, 1998, Is olfactory reference syndrome on the obsessive-compulsive spectrum? Two cases and a discussion, Journal of Neuropsychiatry and Clinical Neuroscience, 10, 96, 10.1176/jnp.10.1.96 · DOI
  90. Stein, 2001, Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study, American Journal of Psychiatry, 158, 1725, 10.1176/appi.ajp.158.10.1725 · DOI · Paper page
  91. Stein, 2002, Predictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials, Journal of Clinical Psychiatry, 63, 152, 10.4088/JCP.v63n0211 · DOI · Paper page
  92. Turner, 1995, Two-year follow-up of social phobias treated with Social Effectiveness Therapy., Behaviour Research and Therapy, 33, 553, 10.1016/0005-7967(94)00086-Y · DOI
  93. Ameringen, 1996, Busiprone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia, Journal of Affective Disorders, 39, 115, 10.1016/0165-0327(96)00030-4 · DOI
  94. Ameringen, 2001, Pharmacotherapy of social anxiety disorder at the turn of the millennium., Psychiatric Clinics of North America, 24, 783, 10.1016/S0193-953X(05)70263-X · DOI
  95. Wardle, 1990, Behavior therapy and benzodiazepines: allies or antagonists?, British Journal of Psychiatry, 156, 163, 10.1192/bjp.156.2.163 · DOI · Paper page

Cited by

See all 102

Metadata

Authors
Stein, D. J., Ipser, J. C., & van Balkom, A. J.
Venue
Cochrane Database of Systematic Reviews
Published
2004-10-18
Issue
4
Pages
CD001206-CD001206
ISSN
1361-6137 (ISSN-L)
OpenAlex
W1583884694
Cited by
102
References
19
Type
reference entry
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.